Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Solagift is a Russian biotechnology company that specializes in the research, development, and industrial production of bioactive substances derived from coniferous trees. The company is recognized as a global leader in the extraction of polyprenols, which serve as vital precursors to dolichols in the human body, supporting cellular membrane integrity and protein glycosylation. Their primary pharmaceutical product, Ropren, is a plant-derived hepatoprotector approved for treating various liver pathologies, including hepatitis and fatty liver disease. Solagift utilizes advanced supercritical CO2 extraction techniques to produce high-purity botanical extracts for the pharmaceutical, nutraceutical, and cosmetic sectors. The company operates out of Tomsk, leveraging a strong scientific foundation to explore new applications for forest-derived compounds in neurology and immunology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Solagift.